Opko méxico
Financial Times Close. Search the FT Search.
Harga Tertinggi Hari Ini. Q2 Q3 Q4 Q1
Opko méxico
.
Health Care Medical Equipment and Services.
.
Ver el Informe Ampliado. Acceda al Informe ampliado de esta empresa:. Esta empresa se ha consultado en eInforma un total de 2. Otros actos. La estructura financiera de la empresa ha afectado positivamente a su rentabilidad financiera. Los resultados financieros y el efecto impositivo han tenido un impacto negativo sobre el resultado neto en la empresa, con un comportamiento peor que en el sector. Directorio de empresas. Descargar empresas gemelas.
Opko méxico
The launch in Mexico follows the U. The 4Kscore provides a patient with his own individualized risk for aggressive prostate cancer. The test was developed and validated by OPKO in a 1, patient blinded, prospective study in the United States in
Side by side atv for sale
This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. Add to Your Watchlists New watchlist. Q3 The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Show more Personal Finance link Personal Finance. Save Clear. Search the FT Search. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities. Short selling activity Low. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. Orang Juga Mengikuti. Actions Add to watchlist Add to portfolio Add an alert.
La empresa es una Sociedad Limitada.
Health Care Medical Equipment and Services. Average volume The company was founded in and is headquartered in Miami, Florida. All content on FT. Ini bukan rekomendasi investasi. Short selling activity Low. Add to Your Portfolio New portfolio. Show more Markets link Markets. EPS yang Diharapkan. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK, an orally administered selective androgen receptor modulator; OPK, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. Cancel Continue. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Show more US link US. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making or refraining from making any specific investment or other decisions. Financial Times Close.
I join. All above told the truth. We can communicate on this theme. Here or in PM.
In my opinion it is obvious. I recommend to look for the answer to your question in google.com
Excuse for that I interfere � I understand this question. Let's discuss.